Harvard Heart Letter

Beyond statins: New medicines for hard-to-manage cholesterol

Statins succeed as the first-line drug therapy to lower LDL cholesterol levels in most people who need medications, but at least one in five individuals still fails to reach the desired target. A novel class of drugs called PCSK9 inhibitors may pick up the slack where other cholesterol medications leave off. The first group of people to benefit will be those with a condition known as familial hypercholesterolemia (FH), an inherited disorder that affects about one in 200 individuals. These people carry a genetic variant that causes cholesterol levels to skyrocket.
To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »